Class summary at a glance.

Every drug in the Dihydrofolate Reductase Inhibitor Antimalarial class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $11.6Mcombined across class
Total Rx claims: 803205 unique beneficiaries
Generic mfrs (active): 3across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Pyrimethamine

Brand: Daraprim · 803 Part D claims (CY24) · 205 beneficiaries · First FDA approval: 1953-01-23

3 generic mfrs 280 plans require PA

Low NADAC$137.01

→

Avg plan cost$137.01

Part D spend $11.6M 1× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.